Sign in

Lost your password?

Samsung Biologics

Last updated: 11.02.2019


Samsung Biologics was established in April 2011 and is headquartered in Incheon, South Korea.

Together with its subsidiaries, Samsung Biologics engages in the research, development, and commercialization of biopharmaceutical products worldwide.

The company develops immunosuppressant biosimilars, such as Enbrel under the Brenzys and Benepali brand names; Remicade under the Renflexis and Flixabi brands; and Humira under the Hadlima and Imraldi brand names. The company also offers Herceptin, a biosimilar for the treatment of breast cancer under the Samfenet and Ontruzant brand name.

In addition, the company offers process development services, including upstream, downstream, and analytical technology; cell culture and purification; aseptic fill and finish, lyophilization, and support processes; quality and compliance, and quality control; and project management services.

Further, it provides contract manufacturing services for mammalian bulk manufacturing. Samsung Biologics Co.,Ltd. has a partnership agreement with the Immunomedics, Inc. to manufacture hRS7, an Immunomedics humanized antibody.



We use cookies to ensure that we give you the best experience on our site. For more info click here